

## 2024 Current Fiscal Year Report: National Science Advisory Board for Biosecurity

Report Run Date: 04/19/2024 04:09:07 PM

### 1. Department or Agency

Department of Health and Human  
Services

### 2. Fiscal Year

2024

### 3. Committee or Subcommittee

National Science Advisory Board for  
Biosecurity

### 3b. GSA

### Committee No.

21482

### 4. Is this New During Fiscal Year?

### 5. Current Charter

### 6. Expected Renewal Date

### 7. Expected Term Date

No 04/07/2022 04/07/2024

### 8a. Was Terminated During Fiscal Year?

No

### 8b. Specific Termination Authority

### 8c. Actual Term Date

### 9. Agency Recommendation for Next Fiscal Year

Continue

### 10a. Legislation Req to Terminate?

Not Applicable

### 10b. Legislation Pending?

Not Applicable

### 11. Establishment Authority

Authorized by Law

### 12. Specific Establishment Authority

42 USC 217a, Section 222 of  
the PHS, PAHPA PL  
109-417, Section 205, 120  
Stat. 2851

### 13. Effective Date

### 14. Committee Type

### 14c. Presidential?

11/22/1962 Continuing No

### 15. Description of Committee

Scientific Technical Program  
Advisory Board

### 16a. Total Number of Reports

No Reports for  
this Fiscal Year

### 17a. Open

### 17b. Closed

### 17c. Partially Closed

### Other Activities

### 17d. Total

### Meetings and Dates

No Meetings

	Current FY	Next FY
<b>18a(1). Personnel Pmts to Non-Federal Members</b>	\$0.00	\$0.00
<b>18a(2). Personnel Pmts to Federal Members</b>	\$0.00	\$0.00
<b>18a(3). Personnel Pmts to Federal Staff</b>	\$0.00	\$0.00
<b>18a(4). Personnel Pmts to Non-Member Consultants</b>	\$0.00	\$0.00
<b>18b(1). Travel and Per Diem to Non-Federal Members</b>	\$0.00	\$0.00
<b>18b(2). Travel and Per Diem to Federal Members</b>	\$0.00	\$0.00
<b>18b(3). Travel and Per Diem to Federal Staff</b>	\$0.00	\$0.00
<b>18b(4). Travel and Per Diem to Non-member Consultants</b>	\$0.00	\$0.00
<b>18c. Other(rents,user charges, graphics, printing, mail, etc.)</b>	\$0.00	\$0.00
<b>18d. Total</b>	\$0.00	\$0.00
<b>19. Federal Staff Support Years (FTE)</b>	0.00	0.00

**20a. How does the Committee accomplish its purpose?**

The purpose of the National Science Advisory Board for Biosecurity (NSABB) is to provide, as requested, advice, guidance, and recommendations regarding biosecurity oversight of dual use research, defined as biological research with legitimate scientific purpose that may be misused to pose a biologic threat to public health and/or national security. The NSABB will provide advice on and recommend specific strategies for the efficient and effective oversight

of federally conducted or supported dual use biological research, taking into consideration both national security concerns and the needs of the research community to foster continued rapid progress in public health and agricultural research. Toward this end, the NSABB will also provide strategies to raise awareness of dual use issues relevant to the life science and related interdisciplinary research communities. In addition, pursuant to Section 205 of the Pandemic and All-Hazards and Preparedness Act (PAHPA), when requested by the Secretary of Health and Human Services (HHS), the NSABB shall also provide to relevant Federal departments and agencies, advice, guidance, or recommendations concerning (1) a core curriculum and training requirements for workers in maximum containment and biological laboratories; and (2) periodic evaluation of maximum containment biological laboratory capacity nationwide and assessments of the future need for increased laboratory capacity.

**20b. How does the Committee balance its membership?**

In advising on the efficient and effective oversight of dual use life sciences research, the NSABB must consider both public health and national security needs and the needs of the research community. Because this requires a diverse range of expertise, the NSABB will consist of not more than 25 voting members who provide broad expertise in areas such as molecular biology/genomics, microbiology (bacteriology), microbiology (virology), clinical Infectious diseases/diagnostics, institutional and/or laboratory, biosafety and biosecurity, public health/epidemiology, health physicist/radiation safety, pharmaceutical production, veterinary

medicine, plant health, food production, bioethics, national security, military biodefense programs and military medicine, intelligence, biodefense, law and law enforcement, academia, scientific publishing, export controls, industry perspective and public perspective. In appointing these members, careful consideration is also given to geographic, gender, and race/ethnicity balance. In addition, nonvoting ex officio members represent HHS.

**20c. How frequent and relevant are the Committee Meetings?**

Meetings of the NSABB will be held approximately three times within a fiscal year and may be convened on an as-needed basis. The NSABB held 1 virtual meeting on 1/27/2023. There was 1 two-day Workgroup meeting held at the White House on 05/15-16/2023. The NSABB produced one report this fiscal year that included 12 recommendations made by the Committee.

**20d. Why can't the advice or information this committee provides be obtained elsewhere?**

The NSABB is the only Federal advisory committee chartered to advise the Federal Government on the management and oversight of dual use research; a constantly evolving challenge with significant implications for national biodefense, biosafety and biosecurity, and maintenance of a strong U.S. bioeconomy. The NSABB brings together a unique and broad range of perspectives and expertise, including biomedical, plant, and animal research; biosecurity, law, law enforcement, scientific publishing, biodefense, and intelligence.

**20e. Why is it necessary to close and/or partially closed committee meetings?**

N/A

## 21. Remarks

Membership: Nicolette Louissaint ended her term early on 10/12/2022. Administrative Extensions: The following members have been administratively extended until 12/06/2023: Drs. Bernard, Denison, Fletcher, Grabenstein, Parker, and Silver. Dr. London has been administratively extended until 12/11/2023. Ex Officio: Dr. David Hassell's term ended on 6/14/2023. NIAID Acting Director, Dr. Hugh Auchincloss Jr. was appointed as Ex Officio on 01/01/2023 to replace Dr. Anthony Fauci who retired 12/31/2022. NIAID Director, Dr. Jeanne Marrazzo was appointed as Ex Officio of the committee to replace the former NIAID Acting Director and NSABB Ex Officio, Dr. Hugh Auchincloss Jr. on 09/25/2023. The Designated Federal Officer and Committee Decision Maker positions are held by the same individual based on assigned duties within the IC. Per the Charter, NSABB will consist of not more than 25 voting members and there may be nonvoting ex officio members from HHS. At this time, there are 13 voting members and 2 ex officio members. The number of Ex Officios could change as the Charter doesn't specify a maximum number for ex officio members.

### Designated Federal Officer

Cari Young Acting Director, Division of Biosafety, Biosecurity, and Emerging Biotechnology Policy

Committee Members	Start	End	Occupation	Member Designation
Benjamin, Shannon	10/24/2021	06/14/2024	Associate Director	Special Government Employee (SGE) Member

Bernard, Kenneth	10/30/2017	12/06/2023	Retired Consultant	Special Government Employee (SGE) Member
Denison, Mark	09/14/2018	12/06/2023	Edward Stahlman Professor of Pediatrics, Professor of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center	Special Government Employee (SGE) Member
Egan, Christina	10/24/2021	06/14/2024	Deputy Director and Chief	Special Government Employee (SGE) Member
Fletcher, Jacqueline	01/21/2020	12/06/2023	Regents Professor Emerita, National Institute for Microbial Forensics & Food and Agricultural Biosecurity, Oklahoma State University	Special Government Employee (SGE) Member
Grabenstein, John	03/07/2019	12/06/2023	Executive Director, Vaccine Dynamics SP	Special Government Employee (SGE) Member
Haynes, Karmella	10/24/2021	06/14/2024	Assistant Professor	Special Government Employee (SGE) Member
Kuhnert-Tallman, Wendi	05/01/2021	09/30/2024	Senior Advisor for Laboratory Science, Office of the Deputy Director for Infectious Disease, Center for Disease Control and Prevention	Ex Officio Member

Levinson, Rachel	12/19/2021	06/14/2024	Executive Director of National Research Initiatives	Special Government Employee (SGE) Member
London, Alex	08/16/2020	12/11/2023	Professor of Ethics and Philosophy Director, Center for Ethics and Policy Carnegie Mellon University	Special Government Employee (SGE) Member
Madad, Syra	10/24/2021	06/14/2024	Senior Director	Special Government Employee (SGE) Member
Marrazzo, Jeanne	09/25/2023	09/24/2027	Director, National Institute of Allergy and Infectious Diseases, NIH	Ex Officio Member
Metzger, Dennis	10/24/2021	06/14/2024	Professor and Chair	Special Government Employee (SGE) Member
Parker, Gerald	01/02/2020	12/06/2023	Associate Dean for Global One Health, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University	Special Government Employee (SGE) Member
Pillai, Segaran	01/14/2021	12/31/2023	Director, Office of the Commissioner, U.S. Food and Drug Administration	Ex Officio Member

			Professor of Biochemistry and Systems Biology, Member, Harvard University Wyss Institute of Biologically Inspired Engineering, Department of Systems Biology, Harvard Medical School	Special Government Employee (SGE) Member
Silver, Pamela	01/21/2020	12/06/2023		

**Number of Committee Members Listed: 16**

**Narrative Description**

The purpose of the National Science Advisory Board for Biosecurity (NSABB) is to provide advice, guidance, and leadership regarding biosecurity oversight of dual use research, defined as biological research with legitimate scientific purpose that may be misused to pose a threat to public health and/or national security. The NSABB will advise the Secretary, HHS, and the Director of the National Institutes of Health (NIH). In addition, when requested by the Secretary, HHS, the NSABB will advise the heads of all Federal entities that conduct, support, or have an interest in life sciences research on the matters delineated in Section 205 of the Pandemic and All-Hazards and Preparedness Act. The NSABB advises on and recommends specific strategies for the efficient and effective oversight of federally conducted or supported dual use biological research, taking into consideration both national security concerns and the needs of the research community.

**What are the most significant program outcomes associated with this committee?**

Checked if  
Applies

- |                                  |                                     |
|----------------------------------|-------------------------------------|
| Improvements to health or safety | <input checked="" type="checkbox"/> |
| Trust in government              | <input checked="" type="checkbox"/> |
| Major policy changes             | <input checked="" type="checkbox"/> |
| Advance in scientific research   | <input type="checkbox"/>            |



- |   |                                     |
|---|-------------------------------------|
| Effective grant making                            | <input type="checkbox"/>            |
| Improved service delivery                         | <input type="checkbox"/>            |
| Increased customer satisfaction                   | <input type="checkbox"/>            |
| Implementation of laws or regulatory requirements | <input type="checkbox"/>            |
| Other   | <input checked="" type="checkbox"/> |

### Outcome Comments

The Committee is advises on significant policy issues that have the potential to affect the oversight of all federally-funded life sciences research. In addition, the policies that are informed by its recommendations help ensure that the scientific community conducts and communicates its research in a responsible manner.

### What are the cost savings associated with this committee?

Checked if Applies

- |                            |                                     |
|----------------------------|-------------------------------------|
| None                       | <input type="checkbox"/>            |
| Unable to Determine        | <input checked="" type="checkbox"/> |
| Under \$100,000            | <input type="checkbox"/>            |
| \$100,000 - \$500,000      | <input type="checkbox"/>            |
| \$500,001 - \$1,000,000    | <input type="checkbox"/>            |
| \$1,000,001 - \$5,000,000  | <input type="checkbox"/>            |
| \$5,000,001 - \$10,000,000 | <input type="checkbox"/>            |
| Over \$10,000,000          | <input type="checkbox"/>            |
| Cost Savings Other         | <input type="checkbox"/>            |

### Cost Savings Comments

This Committee provides advice, guidance, and leadership as stated in the narrative above. It can take many years for the impacts of these recommendations to come to fruition.

### What is the approximate Number of recommendations produced by this committee for the life of the committee?

241

### Number of Recommendations Comments

In FY2023 the NSABB held 1 virtual meeting on 1/27/2023. There was 1 two-day workgroup meeting held at the White House on 05/15-16/2023. The NSABB produced one report this fiscal year that included 12 recommendations made by the Committee.

**What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?**

0%

**% of Recommendations Fully Implemented Comments**

Due to the large breadth and complexity of the recommendations made by this committee on policy and program areas, NIH staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee's activities.

**What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?**

0%

**% of Recommendations Partially Implemented Comments**

Due to the large breadth and complexity of the recommendations made by this committee on policy and program areas, NIH staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee's activities.

**Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?**

Yes ☒ No ☐ Not Applicable ☐

**Agency Feedback Comments**

Information is provided to the public at each meeting. The public can view information related to the Committee through the committee's official website.

**What other actions has the agency taken as a result of the committee's advice or recommendation?**

Checked if Applies

Reorganized Priorities	<input checked="" type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input checked="" type="checkbox"/>

**Action Comments**

The NSABB will advise the Secretary, HHS, and the Director of the National Institutes of

Health (NIH). In addition, when requested by the Secretary, HHS, the NSABB will advise the heads of all Federal entities that conduct, support, or have an interest in life sciences research on the matters delineated in Section 205 of the Pandemic and All-Hazards and Preparedness Act.

**Is the Committee engaged in the review of applications for grants?**

No

**Grant Review Comments**

N/A

**How is access provided to the information for the Committee's documentation?**

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input type="checkbox"/>
Other	<input type="checkbox"/>

**Access Comments**

N/A